fbpx
Connect with us

NEWS

Generex Biotechnology Corporation (OTCMKTS:GNBT) Launches An Integrated Health Management Platform

Published

on

In a new wake of events, Generex Biotechnology Corporation (OTCMKTS:GNBT) has introduced a platform, which primarily deals with in-depth patient health management services. NuGenerex Medical Marketing (NMM) is a significant project and will act as the company’s sales and marketing backbone support. Some of the areas it will handle include patient identification, acquisition, and onboarding. Its establishment comes at a time when hundreds of pharmaceuticals businesses are seeking measures to accelerate their growth and expansion.

Generex is seeking entry into the U.S market and the reason it has embraced a multi-channel acquisition strategy. The strategy has been running for several months the main target being assets and organizations, which offer a series of services.

NMM will provide national marketing and customer service capabilities

Generex will benefit in a million ways from the new establishment; thanks to its capabilities. NMM plans to roll out an extensive pharmacy backbone, which will in return offer a nationwide footprint. It will have an integration with Customer Relationship Management (CRM) dashboard for Generex. Through a dedicated call-center, the integration will support the company’s ongoing patient support services and particularly the chronic care management.

In addition, NMM will offer compliant direct-to-patient outreach services, which are fully compliant with the market needs. An accomplished team, which has deep experience in pharmaceutical and medical device sales will support the new move. The team is trained in HIPAA, FTC and it has full exposure of the FDA rules. Thus it will ensure adherence to processes and procedures in the delivery of medical services.

The realization of a vision for a new healthcare enterprise

For the last two years, Generex has worked diligently to enhance the delivery of its services. Its emphasis is on unlocking new platforms, which will offer end-to-end treatment and services solutions. This far, the company is happy with its achievements according to the Chief Executive Officer Joseph Moscato.

He says, “We are delighted to launch NuGenerex Medical Marketing as another step in our overall corporate strategy to provide end-to-end solutions that optimize patient health outcomes.”

Meanwhile, the company has vowed to continue closing on the acquisition of additional operating assets. Its expectation is to meet the initial listing requirements one of them being a lucrative enterprise with a presence in another 23 states.

Continue Reading
Advertisement

NEWS

Earth Science Tech Inc. (OTCMKTS:ETST) Has A New Update Regarding Its Cannabidiol Patents

Published

on

Earth Science Tech Inc. (OTCMKTS:ETST) has shared a new update regarding its cannabidiol (“CBD”) patents. The biotech company says that it is ready to launch its two CBD-based nutraceutical formulas. They include a neuron protector and a breast protector. However, there is so much that is yet to hit the public domain as explained by ETST president and CEO Nickolas Tabraue.

Tabraue outlines, “We will provide more details on the progress of these formulas in the near future.” At the same time, the company has also promised to share the way forward regarding its first CBD-based pharmaceutical product.

The use of CBD and will open the doors for the research

For a very long time, the cannabis industry was for the most successful entrepreneurs in history. However, the market is now open to people from all walks of life thanks to the massive expansion. Thus the need for accelerated research activities. Tabraue affirms that research will result in the development of a revolutionary CDB-based pharmaceutical drug. This will give Earth Science Tech an upper hand in spreading its presence globally.

The formulas will undergo an in vitro testing to establish their biological activities. TransBiotech will carry out the testing, which will compare the level of protection of the hemp oil provided by ETST. The comparison will be against the company’s hemp oil with other natural ingredients. Any positive results will increase its current recognition as a world leader in the CBD space.

Earth Science Tech, Inc. offers the highest quality high-grade full spectrum cannabinoid oil

The company’s Chief Science Officer Dr. Michel Aubé claims that they have a much deeper understanding of cannabinoids compared to their competitors. Besides, the company has received an endorsement verifying that CBD is not addictive. Apparently, CBD was previously under schedule 1 drug classification before its recent shift by U.S. Drug Enforcement Agency (DEA). Nonetheless, there are those CBD products, which DEA has maintained that they are controlled substances. Hence they retain their status in the Schedule 1 list

ETST’s core activities include the formulation, marketing, and distribution of CBD oil. It owns four subsidiaries, which are quickly expanding their operations in the pharmaceutical sectors.

Continue Reading

NEWS

ELEV8 BRANDS (OTCMKTS:VATE) Expands Its Business Operations

Published

on

ELEV8 BRANDS (OTCMKTS:VATE) focuses in the manufacture of hemp and CBD-related products. These include the CBD Lotions, hemp Cold Brew, CBD salve, hemp tea, hemp coffee as well as the CBD Tinctures. Most of these quality products are useful in the health and wellness markets. This business guru has acquired the newly formed One Utopia, LLC.

The state of affairs

ELEV8 BRANDS outlines that it has settled on One Utopia, LLC as the new name for the brick and mortar locations that will focus on the sale of products that 02 Breathe sells currently. Some of these products include massage products, salt lamps, essential oils and above all CBD products.

It was recently that this company signed a one-year lease for a store location in Cocoa Village at 409 Delannoy Avenue. Cocoa village is a historical village where activities such as dining, shopping and entertainment take place.

One Utopia has acquired a brand-new mobile coffee trailer. Some of the products this company will manufacture include mushroom coffee, matcha lattes, hemp coffee drinks, tea and other beverages. Most of them come with a wide range of benefits. Elev8 Brands states that the new mobile coffee trailer is a great addition. Eventually, it admits it that it has never enjoyed such impressive presence before.

Medico’s perspective

The CEO Ryan Medico opined, “We have a lot of moving parts right now and are very excited about the growth. Getting product delivered up to Amazon facilities in Canada and finishing up our audit is our highest priority.”

The official advocates for the capitalization of the expansion. To achieve the set objective, the company has brought on board a full time National Sales Manager. The new official will take care of account management. It also wants to pay a great focus on the pursuance of trade shows. It has enough personnel to help it accomplish this objective.

ELEV8 BRANDS says it will do everything possible to ensure that it experiences exponential growth over the coming months. There are positions that will compel the company to employ persons with extensive sales background.

Continue Reading

NEWS

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Announces A Program Targeting GVHD Treatment

Published

on

Kalytera Therapeutics Inc (OTCMKTS:KALTF) today spoke in relation to its lead product development program. The company seeks to undertake an evaluation on cannabidiol (“CBD”).

It hopes to discover its role towards the treatment and the prevention of acute GVHD. This is a life-threatening condition that has so far claimed quite a significant number of lives globally. Experts say it usually occurs following a bone marrow transplant.

A closer outlook

The transplanted donor cells attack several body organs. These organs include the GI tract, eyes, lungs, liver and the skin. A patient struggling with GVHD may suffer from infections and chronic illnesses. Such patients may become disabled and even risk a reduced quality of life.

Acute GVHD is a serious condition, but a lot of people say the FDA hasn’t yet taken the matter with the seriousness it deserves. They think that it should by now have approved therapies to help with either the prevention or the treatment.

A lot of patients are opposed to the consumption of ingredients that cause them to encounter cognitive effects or euphoria. Kalytera is currently testing a CBD formulation that will help with the prevention of acute GVHD.

Latest developments

Kalytera is working on two development programs at the moment. The first one has to do with the evaluation of CBD and its role in helping prevent acute GVHD. The other one will pay focus to the evaluation of CBD in line with the treatment of acute GVHD.

Kalytera says that the prevention program is currently underway. It is on the second phase and patients have been handpicked from three clinical sites situated in Israel. After completing this phase, the business will be making preparations for the pivotal Phase 3 clinical study.

The CEO of Kalytera Robert Farrell says that they are working on top strategies that will help them boost their shareholder value. He believes the best way to go about it is by advancing this company’s programs in GVHD. He insists there is need to drive them to Phase 3 status.

Kalytera has also unveiled its grant of stock options to the various employees and directors as well.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories